Bangladesh - English - DGDA (Directorate General of Drug Administration)

opsonin pharma limited - azelastine + fluticasone propionate - nasal spray - 125 mcg + 50 mcg/metered inhalation

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio bussie - olanzapina - olanzapina....10,00 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

osl pharma ltd. - azelastin hydrochloride - nasal spray - 137 mcg/metered inhalation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - flubendiamide - suspension concentrate - flubendiamide benzene active 480.0 g/l - insecticide - beetroot | brassica spp. or cole crop | brassica vegetables | broccoli | brussels sprouts | burdock | cabbage | capsicum or pepp - cabbage moth | cabbage white butterfly | cluster caterpillar | cucumber moth | helicoverpa spp. | potato moth | soybean looper | tomato leaf miner | corn earworm | cotton bollworm | diachrysia orichalcea | diamondback moth | heliothis | native budworm | potato tuber moth | tobacco budworm | tobacco leafminer | tomato grub

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

el dawlia ico. international company for medical necessities, egypt - edta vaccutainer -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

generics & specialities limited, tanzania - belt -

South Africa - English - myHealthbox

bayer ag - flubendiamide (phthalic acid diamide)  480 g/l

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; indigo carmine aluminium lake; hypromellose; iron oxide yellow; triacetin; iron oxide red; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.